Bentham Science Logo

Current Cancer Drug Targets

Volume 19, 11 Issues, 2019
ISSN: 1873-5576 (Online)
ISSN: 1568-0096 (Print)
This journal supports open access

Aims & Scope

Current Cancer Drug Targets aims to cover all the latest and outstanding developments on the medicinal chemistry, pharmacology, molecular biology, genomics and biochemistry of contemporary molecular drug targets involved in cancer, e.g. disease specific proteins, receptors, enzymes and genes.

Current Cancer Drug Targets publishes original research articles, letters, reviews, drug clinical trial studies and guest edited thematic issues written by leaders in the field covering a range of current topics on drug targets involved in cancer.

As the discovery, identification, characterization and validation of novel human drug targets for anti-cancer drug discovery continues to grow; this journal has become essential reading for all pharmaceutical scientists involved in drug discovery and development.

Current Cancer Drug Targets

,

Volume 19

-

Number 2



Biography   Open Access



Review Article



Review Article



Review Article

Cellular Senescence-Inducing Small Molecules for Cancer Treatment

, 19(2): 109 - 119

Peng Liu, Ziwen Lu, Yanfang Wu, Dongsheng Shang, Zhicong Zhao, Yanting SHEN, Yafei Zhang, Feifei Zhu , Hanqing Liu* and Zhigang Tu*


DOI: 10.2174/1568009618666180530092825


Review Article



Research Article



Articles Ahead of Print



Nanotherapy Targeting the Tumor Microenvironment


Bo-Shen Gong, Rui Wang, Hong-Xia Xu, Ming-Yong Miao* and Zhen-Zhen Yao*


View Abstract View on PubMed


Zoledronic Acid Inhibits the RhoA-mediated Amoeboid Motility of Prostate Cancer Cells


Laura Pietrovito, Giuseppina Comito, Matteo Parri, Elisa Giannoni, Paola Chiarugi and Maria Letizia Taddei*


View Abstract View on PubMed


Gefitinib Represses JAK-STAT Signaling Activated by CRTC1-MAML2 Fusion in Mucoepidermoid Carcinoma Cells


Yufeng Wu*, Zhen He, Shaomei Li, Hong Tang, Lili Wang, Sen Yang, Bing Dong, Jianjun Qin, Yue Sun, Han Yu, Yu Zhang, Yi Zhang, Yongjun Guo and Qiming Wang


View Abstract View on PubMed






Overexpression of Nemo-like Kinase Promotes the Proliferation and Invasion of Lung Cancer Cells and Indicates Poor Prognosis


Lei Lei, Yuan Wang, Yi-Wen Zheng, Liang-Ru Fei, Hao-Yue Shen, Zhi-Han Li, Wen-Jing Huang, Juan-Han Yu and Hong-Tao Xu


View Abstract View on PubMed


Editor's Choice



Specific Targeting of HER2-Positive Head and Neck Squamous Cell Carcinoma Line HN5 by Idarubicin-ZHER2 Affibody Conjugate

, 2019; 19(1): 65 - 73

Marzieh Ghanemi, Aminollah Pourshohod, Mohammad Ali Ghaffari, Alireza kheirollah, Mansour Amin, Majid Zeinali* and Mostafa Jamalan*


DOI: 10.2174/1568009617666170427105417





p53-Mdm2 Interaction Inhibitors as Novel Nongenotoxic Anticancer Agents

, 2018; 18(8): 749 - 772

Surendra Kumar Nayak*, Gopal L. Khatik, Rakesh Narang, Vikramdeep Monga and Harish Kumar Chopra


DOI: 10.2174/1568009617666170623111953



Regulation of MicroRNAs by Phytochemicals: A Promising Strategy for Cancer Chemoprevention

, 2018; 18(7): 640 - 651

Sadegh Babashah*, Babak Bakhshinejad, Maryam Tahmasebi Birgani, Katayoon Pakravan and William C. Cho*


DOI: 10.2174/1568009617666170623124710



Oncolytic Tanapoxvirus Expressing Interleukin-2 is Capable of Inducing the Regression of Human Melanoma Tumors in the Absence of T Cells

, 2018; 18(6): 577 - 591

Tiantian Zhang, Dennis H. Kordish, Yogesh R. Suryawanshi, Rob R. Eversole, Steven Kohler, Charles D. Mackenzie and Karim Essani*


DOI: 10.2174/1568009617666170630143931



The Real Impact of Target Therapy in Breast Cancer Patients: Between Hope and Reality

, 2018; 18(5): 480 - 498

Sebastiano Bordonaro, Massimiliano Berretta, Antonino Carmelo Tralongo, Silvia Clementi, Brigida Stanzione and Paolo Tralongo*


DOI: 10.2174/1568009617666170209100322



Cell-derived Exosomes as Promising Carriers for Drug Delivery and Targeted Therapy

, 2018; 18(4): 347 - 354

Xinyi Wang, Haiyang Zhang, Haiou Yang, Ming Bai, Tao Ning, Shuang Li, Jialu Li, Ting Deng, Guoguang Ying* and Yi Ba*


DOI: 10.2174/1568009617666170710120311



Open Access Articles

Linc01638 Promotes Tumorigenesis in HER2+ Breast Cancer

, 2019; 19(1): 74 - 80

Peng Liu, Hailin Tang, Jiali Wu, Xingsheng Qiu, Yanan Kong, Lijuan Zhang, Xinhua Xie* and Xiangsheng Xiao*








Platycodin D Induces Tumor Growth Arrest by Activating FOXO3a Expression in Prostate Cancer in vitro and in vivo

, 2014; 14(9): 860 - 871

Rui Zhou, Zongliang Lu, Kai Liu, Jing Guo, Jie Liu, Yong Zhou, Jian Yang, Mantian Mi and Hongxia Xu




Pleiotropic Role of HSF1 in Neoplastic Transformation

, 2014; 14(2): 144 - 155

Natalia Vydra, Agnieszka Toma and Wieslawa Widlak






β-Catenin Knockdown in Liver Tumor Cells by a Cell Permeable Gamma Guanidine-based Peptide Nucleic Acid

, 2013; 13(8): 867 - 878

Evan Delgado, Raman Bahal, Jing Yang, Jung M. Lee, Danith H Ly and Satdarshan P. S. Monga




Signal Transduction in Human Cutaneous Melanoma and Target Drugs

, 2013; 13(8): 843 - 866

Anatoly B. Uzdensky, Svetlana V. Demyanenko and Mikhail Y. Bibov




Use of Single Nucleotide Polymorphism Array Technology to Improve the Identification of Chromosomal Lesions in Leukemia

, 2013; 13(7): 791 - 810

Ilaria Iacobucci, Annalisa Lonetti, Cristina Papayannidis and Giovanni Martinelli




Autophagy in Chronic Myeloid Leukaemia: Stem Cell Survival and Implication in Therapy

, 2013; 13(7): 724 - 734

Gudmundur V. Helgason, Arunima Mukhopadhyay, Maria Karvela, Paolo Salomoni, Bruno Calabretta and Tessa L. Holyoake




New Insights Into Biology of Chronic Myeloid Leukemia: Implications in Therapy

, 2013; 13(7): 711 - 723

Michele Cea, Antonia Cagnetta, Alessio Nencioni, Marco Gobbi and Franco Patrone






Most Cited Articles

Epi-Drugs and Epi-miRs: Moving Beyond Current Cancer Therapies

, 2016; 16(9): 773-788.

Reza Salarinia, Amirhossein Sahebkar, Mostafa Peyvandi, Hamid Reza Mirzaei, Mahmoud Reza Jaafari, Maryam Matbou Riahi, Hamed Ebrahimnejad, Javid Sadri Nahand, Jamshid Hadjati, Mobina Ostadi Asrami, Sara Fadaei, Rasoul Salehi and Hamed Mirzaei


DOI: 10.2174/1568009616666151207110143




Indoleamine 2,3-dioxygenase (IDO): Biology and Target in Cancer Immunotherapies

, 2016; 16(9): 755-764.

Senthamil R. Selvan, John P. Dowling, William K. Kelly and Jianqing Lin


DOI: 10.2174/1568009615666151030102250


Targeting ABCB1 and ABCC1 with their Specific Inhibitor CBT-1® can Overcome Drug Resistance in Osteosarcoma

, 2016; 16(3): 261-274.

Marilù Fanelli, Claudia Maria Hattinger, Serena Vella, Elisa Tavanti, Francesca Michelacci, Beth Gudeman, Daryl Barnett, Piero Picci and Massimo Serra


DOI: 10.2174/1568009616666151106120434


Targeting Tumors with Small Molecule Peptides

, 2016; 16(6): 489-508.

Andrew G. Cheetham, Daniel Keith, Pengcheng Zhang, Ran Lin, Hao Su and Honggang Cui


DOI: 10.2174/1568009616666151130214646


Protein Knockdown Technology: Application of Ubiquitin Ligase to Cancer Therapy

, 2016; 16(2): 136-146.

Nobumichi Ohoka, Norihito Shibata, Takayuki Hattori and Mikihiko Naito


DOI: 10.2174/1568009616666151112122502


Regulation of Epithelial-Mesenchymal Transition by E3 Ubiquitin Ligases and Deubiquitinase in Cancer

, 2016; 16(2): 110-118.

Yasumichi Inoue, Yuka Itoh, Koichi Sato, Fumihiro Kawasaki, Chihiro Sumita, Takahito Tanaka, Daisuke Morishita and Hidetoshi Hayashi


DOI: 10.2174/1568009616666151112122126


S-equol, a Secondary Metabolite of Natural Anticancer Isoflavone Daidzein, Inhibits Prostate Cancer Growth In Vitro and In Vivo, Though Activating the Akt/FOXO3a Pathway

, 2016; 16(5): 455-465.

Zongliang Lu, Rui Zhou, Ya Kong, Jiajia Wang, Wanyuan Xia, Jing Guo, Jie Liu, Hailan Sun, Kai Liu, Jian Yang, Mantian Mi and Hongxia Xu


DOI: 10.2174/1568009616666151207105720



CD20-based Immunotherapy of B-cell Derived Hematologic Malignancies

, 2017; 17(5): 423-444.

Dariush Shanehbandi, Jafar Majidi*, Tohid Kazemi*, Behzad Baradaran and Leili Aghebati-Maleki


DOI: 10.2174/1568009617666170109151128





Targeting Signaling Pathways in Chronic Lymphocytic Leukemia

, 2016; 16(8): 669-688.

Alice F. Muggen, Simar P. Singh, Rudi W. Hendriks and Anton W. Langerak


DOI: 10.2174/1568009616666160408145623



Most Accessed Articles


p53-Mdm2 Interaction Inhibitors as Novel Nongenotoxic Anticancer Agents

, 2018; 18(8): 749-772.

Surendra Kumar Nayak*, Gopal L. Khatik, Rakesh Narang, Vikramdeep Monga and Harish Kumar Chopra


DOI: 10.2174/1568009617666170623111953


Ponatinib: A Review of Efficacy and Safety

, 2018; 18(9): 847-856.

Fulvio Massaro, Matteo Molica and Massimo Breccia*


DOI: 10.2174/1568009617666171002142659


Antibody Based EpCAM Targeted Therapy of Cancer, Review and Update

, 2018; 18(9): 857-868.

Shirin Eyvazi, Safar Farajnia*, Siavoush Dastmalchi, Farzad Kanipour, Habib Zarredar and Mojghan Bandehpour


DOI: 10.2174/1568009618666180102102311





A Pan-Cancer Review of ALK Mutations: Implications for Carcinogenesis and Therapy

, 2015; 15(4): 327-336.

Nick Ka Ming Yau, Andrew Yuon Fong, Hiu Fung Leung, Krista Roberta Verhoeft, Qin Ying Lim, Wai Yip Lam, Ian Chi Kei Wong and Vivian Wai Yan Lui


DOI: 10.2174/1568009615666150225123712





Related Journals

Related eBooks

eBooks Catalog